News: Novo Nordisk's Ozempic slows diabetic kidney disease progression in trial, page-2

OVER 4 TIMES MORE LIKELY TO LOSE YOUR SIGHT FROM OZEMPIC THAN OTHER WEIGHT LOSS DRUGS

Wegovy, Ozempic linked with sight-threatening eye disorder in study

Wegovy and Novo's diabetes drugs Ozempic and Rybelsus all contain the same active ingredient, semaglutide, and belong to a class of medications known as GLP1 receptor agonists.

The rate of the eye problem known as nonarteritic anterior ischemic optic neuropathy, or NAION, was 8.9% for those taking semaglutide for type 2 diabetes, compared with 1.8% for patients taking non-GLP-1 diabetes medications, researchers reported in JAMA Ophthalmology.

Among those prescribed semaglutide for overweight or obesity, the rate of the eye condition was 6.7%, versus 0.8% for those receiving other types of medications for weight reduction.



https://www.reuters.com/business/healthcare-pharmaceuticals/wegovy-ozempic-linked-with-sight-threatening-eye-disorder-study-2024-07-03/


Oh yeah! The wonder drug